Study in COPD Patients Evaluating the Quality of Life (TRISNOOZE)

Inclusion Criteria: * Patient has provided written informed consent * Patient is aged 40 years or older * Current or ex-smokers with a smoking history ≥ 10 pack years * Patient is diagnosed with COPD, confirmed by post-bronchodilator spirometry (Tiffeneau index \<0.7; baseline or older spirometry) * Patient is eligible for switch to triple therapy with at least 12 weeks of stable double inhalation therapy (ICS/LABA or LABA/LAMA) prior to enrolment to the study * Patient is starting treatment with Trimbow® upon decision by their physician Exclusion Criteria: * Patients who are hypersensitive to one of the active substances or excipients * Patients who are treated with triple therapy (via single or multiple inhalers) in the last 6 months prior to study enrolment * Patients on ICS, LABA or LAMA monotherapy * Patients with pneumonia and/or a moderate or severe COPD exacerbation not resolved ≥ 14 days prior to screening and ≥ 30 days following the last dose of oral/systemic corticosteroid (if applicable), or a respiratory tract infection not resolved ≥ 7 days prior to screening * Patients participating simultaneously to other clinical trials or studies